Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | UC highlights at ASCO 2022

Richard Cathomas • 5 Jun 2022
ASCO 2022
Bladder Cancer Genitourinary Cancer BCG BCG+N-803 N-803
QUILT 3.032

Richard Cathomas, MD, PhD, Hospital Graubünden, Chur, Switzerland, provides key takeaways in urothelial carcinoma (UC) at this years American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including results of N-803, an IL-15RαFc superagonist, with BCG in BCG-unresponsive non-muscle invading bladder cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Richard Cathomas

0:37
Bladder-sparing approaches in muscle-invasive urothelial carcinoma
Richard Cathomas • 5 Jun 2022
0:35
EV-302: 1L enfortumab vedotin in combination with pembrolizumab
Richard Cathomas • 5 Jun 2022
1:18
Primary analysis of SAKK 06/17: perioperative chemoimmunotherapy with durvalumab for operable MIUC
Richard Cathomas • 5 Jun 2022
2:34
First-line treatments for patients with mHSPC and mCRPC
Richard Cathomas • 27 Sep 2021

Related Videos

0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
1:08
PSMA imaging pre- and post-177Lu-PSMA-617 treatment in mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals